Journal of the Neurological Sciences, 121 (1994) 233–235
Elsevier Science B.V.

Author Index (Vol. 121)

Annas, M., see Dux, R. (121) 74
Antel, J., see Ulvestad, E. (121) 125
Araki, N., see Dezsi, L. (121) 110
Araki, T., see Nagasawa, H. (121) 27
Arendt, G., see Von Giesen, H.-J. (121) 215

Baldwin, R.A., see Dupont-Versteegden, E.E. (121) 203
Bashar Katirji, and Wilbourn, A.J.
High sciatic lesion mimicking peroneal neuropathy at the fibular head (121) 172
Baudrimont, M., see Plante-Bordeneuve, V. (121) 155
Berginer, V.M. and Salen, G.
LDL-apheresis cannot be recommended for treatment of cerebrotendinous xanthomatosis (121) 229
Bergmans, P.L.M., see Kuiper, M.A. (121) 46
Blass, J.P., Markesbery, W.R., Ko, L.-w., DeGiorgio, L., Sheu, K.-F.R. and Darzynkiewicz, Z.
Presence of neuronal proteins in serially cultured cells from autopsy human brain (121) 132
Blennow, K., Fredman, P., Wallin, A., Gottfries, C.G., Frey, H., Pirttilä, T., Skoog, I., Wikkelsö, C. and Svennerholm, L.
Formulas for the quantitation of intrathecal IgG production. Their validity in the presence of blood–brain barrier damage and their utility in multiple sclerosis (121) 90
Bolster, B., see Sharma, S.K. (121) 1

Catz, I., see Warren, K.G. (121) 66
Cooper, J.M., see Sweeney, M.G. (121) 57

Dakshinamurti, K., see Sharma, S.K. (121) 1
Darzynkiewicz, Z., see Blass, J.P. (121) 132
DeGiorgio, L., see Blass, J.P. (121) 132
De Jong, J.M.B.V.
Willem Anton den Hartog Jager (1913–1993) (121) 121
Dezsi, L., Greenberg, J.H., Sladky, J., Araki, N., Hamar, J. and Reivich, M.
Prolonged effects of MK-801 in the cat during focal cerebral ischemia and recovery: survival, EEG activity and histopathology (121) 110
Doyu, M., see Sobue, G. (121) 167
Doyu, M., see Yasuda, T. (121) 97
Duchen, L.W., see Sweeney, M.G. (121) 57
Dupont-Versteegden, E.E., Baldwin, R.A., McCarter, R.J. and Vonlanthen, M.G.
Does muscular dystrophy affect metabolic rate?. A study in *mdx* mice (121) 203
Dux, R., Kindler-Röhrborn, A., Annas, M., Faustmann, P., Lennartz, K. and Zimmermann, C.W.
A standardized protocol for flow cytometric analysis of cells isolated from cerebrospinal fluid (121) 74

Eržen, I., see Pernuš, F. (121) 194

Faustmann, P., see Dux, R. (121) 74
Fernandez, A., see Ordoñez, G. (121) 163
Ferrer, I., see Tortosa, A. (121) 10
Fiszer, U., Mix, E., Fredrikson, S., Kostulas, V., Olsson, T. and Link, H.
$\gamma\delta^+$ T cells are increased in patients with Parkinson's disease (121) 39
Fredman, P., see Blennow, K. (121) 90
Fredrikson, S., see Fiszer, U. (121) 39
Freund, H.J., see Von Giesen, H.-J. (121) 215
Frey, H., see Blennow, K. (121) 90
Furukawa, S., see Hirota, M. (121) 176
Furukawa, Y., see Hirota, M. (121) 176

Gherardi, R.K., see Plante-Bordeneuve, V. (121) 155
Gorin, N.C., see Plante-Bordeneuve, V. (121) 155
Gottfries, C.G., see Blennow, K. (121) 90
Greenberg, J.H., see Dezsi, L. (121) 110

Hamar, J., see Dezsi, L. (121) 110
Hammans, S.R., see Sweeney, M.G. (121) 57
Handa, N., see Hata, R. (121) 79
Harding, A.E., see Sweeney, M.G. (121) 57
Hata, R., Matsumoto, M., Kitagawa, K., Matsuyama, T., Ohtsuki, T., Tagaya, M., Handa, N., Niinobe, M., Mikoshiba, K., Nishimura, T., Yanagihara, T. and Kamada, T.
A new gerbil model of hindbrain ischemia by extracranial occlusion of the bilateral vertebral arteries (121) 79
Hayashi, K., see Hirota, M. (121) 176
Hirota, M., Furukawa, Y., Shinoda, I., Yoneoka, T., Ito, T., Furukawa, S. and Hayashi, K.
Changes in nerve growth factor content of the submaxillary gland in the genetically dystrophic (*mdx*) mouse (121) 176
Hömberg, V. and Huttunen, J.
Muscle tone in Huntington's disease (121) 147
Hori, S., Ohtani, S., Shimizu, T., Ibi, T., Sahashi, K., Nonaka, I., Miyamoto, K. and Tanabe, H.
Multiplicity of abnormal dystrophin in Becker muscular dystrophy. A Becker muscular dystrophy gene frequently produced two smaller sizes of dystrophin (121) 183
Hosokawa, K., see Iwahashi, K. (121) 18
Huttunen, J., see Hömberg, V. (121) 147

Ibi, T., see Hori, S. (121) 183
Ichikawa, Y., see Iwahashi, K. (121) 18
Ichinose, K., see Nishiura, Y. (121) 208
Inao, S., see Kuchiwaki, H. (121) 32
Ito, J.
Somatosensory event-related potentials (ERPs) in patients with different types of dementia (121) 139
Ito, T., see Hirota, M. (121) 176
Iwahashi, K., Suwaki, H., Matsuo, Y., Ichikawa, Y. and Hosokawa, K.
Correspondence of increased debrisoquine 4-monooxygenase activity with seizure-susceptibility in Mongolian gerbils (121) 18

Jablonowski, H., see Von Giesen, H.-J. (121) 215
Jacobs, J.M., see Sweeney, M.G. (121) 57

Kachi, T., see Sobue, G. (121) 167
Kakigi, R., Neshige, R., Matsuda, Y. and Kuroda, Y.
Do patients with Down's syndrome recognize Mickey Mouse? (121) 22
Kallio, A.-K., see Koskinen, T. (121) 50
Kamada, T., see Hata, R. (121) 79
Kennedy, C.R., see Sweeney, M.G. (121) 57
Kindler-Röhrborn, A., see Dux, R. (121) 74
Kitagawa, K., see Hata, R. (121) 79
Ko, L.-w., see Blass, J.P. (121) 132
Kogure, K., see Nagasawa, H. (121) 27
Koskinen, T., Santavuori, P., Sainio, K., Lappi, M., Kallio, A.-K. and Pihko, H.
Infantile onset spinocerebellar ataxia with sensory neuropathy: a new inherited disease (121) 50
Kostulas, V., see Fiszer, U. (121) 39
Kuchiwaki, H., Nagasaka, M., Inao, S. and Sugita, K.
Progression of kaolin-induced hydrocephalus and changes in performance of operant tasks by rats (121) 32
Kuiper, M.A., Visser, J.J., Bergmans, P.L.M., Scheltens, P. and Wolters, E.C.
Decreased cerebrospinal fluid nitrate levels in Parkinson's disease, Alzheimer's disease and multiple system atrophy patients (121) 46
Kuriyama, M. and Mimura, Y.
LDL-apheresis in cerebrotendinous xanthomatosis: reply to the letter by Berginer and Salen. (*J. Neurol. Sci.*, 121 (1994) 229–230) (121) 231
Kuroda, Y., see Kakigi, R. (121) 22

Lappi, M., see Koskinen, T. (121) 50
Lennartz, K., see Dux, R. (121) 74
Link, H., see Fiszer, U. (121) 39
Link, H., see Qiao, J. (121) 190
Llewelyn, J.G., see Patel, N.J. (121) 159

Markesbery, W.R., see Blass, J.P. (121) 132
Matre, R., see Ulvestad, E. (121) 125
Matsuda, Y., see Kakigi, R. (121) 22
Matsumoto, M., see Hata, R. (121) 79
Matsuo, Y., see Iwahashi, K. (121) 18
Matsuyama, T., see Hata, R. (121) 79
McCarter, R.J., see Dupont-Versteegden, E.E. (121) 203
Mikoshiba, K., see Hata, R. (121) 79
Mimura, Y., see Kuriyama, M. (121) 231
Minematsu, K., see Toyoda, K. (121) 222
Mitsuma, T., see Sobue, G. (121) 167
Mitsuma, T., see Yasuda, T. (121) 97
Mix, E., see Fiszer, U. (121) 39
Miyamoto, K., see Hori, S. (121) 183
Morgan-Hughes, J.A., see Sweeney, M.G. (121) 57
Morishima, T., see Sobue, G. (121) 167
Mørk, S., see Ulvestad, E. (121) 125
Mukai, E., see Sobue, G. (121) 167

Nagasaka, M., see Kuchiwaki, H. (121) 32
Nagasato, K., see Nishiura, Y. (121) 208
Nagasawa, H., Araki, T. and Kogure, K.
Alteration of muscarinic acetylcholine binding sites in the post-ischemic brain areas of the rat using in vitro autoradiography (121) 27
Nagataki, S., see Nishiura, Y. (121) 208
Nakamura, T., see Nishiura, Y. (121) 208
Nakazato, M., see Yasuda, T. (121) 97
Neshige, R., see Kakigi, R. (121) 22
Neuen-Jacob, E., see Von Giesen, H.-J. (121) 215
Niinobe, M., see Hata, R. (121) 79
Nishimura, T., see Hata, R. (121) 79
Nishiura, Y., Nakamura, T., Takino, H., Ichinose, K., Nagasato, K., Ohishi, K., Tsujihata, M. and Nagataki, S.
Production of granulocyte-macrophage colony stimulating factor by human T-lymphotropic virus type I-infected human glioma cells (121) 208
Nonaka, I., see Hori, S. (121) 183
Nyland, H., see Ulvestad, E. (121) 125

Ohishi, K., see Nishiura, Y. (121) 208
Ohtani, S., see Hori, S. (121) 183
Ohtsuki, T., see Hata, R. (121) 79
Olsson, T., see Fiszer, U. (121) 39
Ordoñez, G., Fernandez, A., Perez, R. and Sotelo, J.
Low contents of nerve growth factor in serum and submaxillary gland of diabetic mice. A possible etiological element of diabetic neuropathy (121) 163

Patel, N.J., Llewelyn, J.G., Wright, D.W. and Thomas, P.K.
Glucose and leucine uptake by rat dorsal root ganglia is not insulin sensitive (121) 159
Perez, R., see Ordoñez, G. (121) 163
Pernuš, F. and Eržen, I.
Fibre size, atrophy, and hypertrophy factors in vastus lateralis muscle from 18- to 29-year-old men (121) 194
Pihko, H., see Koskinen, T. (121) 50
Pirttilä, T., see Blennow, K. (121) 90
Plante-Bordeneuve, V., Baudrimont, M., Gorin, N.C. and Gherardi, R.K.
Subacute sensory neuropathy associated with Hodgkin's disease (121) 155
Prestien, K., see Von Giesen, H.-J. (121) 215

Qiao, J., Wang, Z.-Y. and Link, H.
β-Bungarotoxin binding protein is immunogenic but lacks myasthenogenicity in rats (121) 190

Reivich, M., see Dezsi, L. (121) 110
Ringelstein, E.B., Weiller, C., Weckesser, M. and Weckesser, S.
Cerebral vasomotor reactivity is significantly reduced in low-flow as compared to thromboembolic infarctions: the key role of the circle of Willis (121) 103
Rivera, R., see Tortosa, A. (121) 10

Sahashi, K., see Hori, S. (121) 183
Sainio, K., see Koskinen, T. (121) 50
Salen, G., see Berginer, V.M. (121) 229
Santavuori, P., see Koskinen, T. (121) 50
Schapira, A.H.V., see Sweeney, M.G. (121) 57
Scheltens, P., see Kuiper, M.A. (121) 46
Sharma, S.K., Bolster, B. and Dakshinamurti, K.
Picrotoxin and pentylene tetrazole induced seizure activity in pyridoxine-deficient rats (121) 1
Sheu, K.-F.R., see Blass, J.P. (121) 132
Shimizu, T., see Hori, S. (121) 183
Shinoda, I., see Hirota, M. (121) 176
Shiomi, K., see Yasuda, T. (121) 97
Skoog, I., see Blennow, K. (121) 90
Sladky, J., see Dezsi, L. (121) 110
Sobue, G., Doyu, M., Morishima, T., Mukai, E., Yasuda, T., Kachi, T. and Mitsuma, T.
Aberrant androgen action and increased size of tandem CAG repeat in androgen receptor gene in X-linked recessive bulbospinal neuronopathy (121) 167
Sobue, G., see Yasuda, T. (121) 97
Sotelo, J., see Ordoñez, G. (121) 163
Sugita, K., see Kuchiwaki, H. (121) 32

Suwaki, H., see Iwahashi, K. (121) 18
Svennerholm, L., see Blennow, K. (121) 90
Sweeney, M.G., Hammans, S.R., Duchen, L.W., Cooper, J.M., Schapira, A.H.V., Kennedy, C.R., Jacobs, J.M., Youl, B.D., Morgan-Hughes, J.A. and Harding, A.E.
Mitochondrial DNA mutation underlying Leigh's syndrome: clinical, pathological, biochemical, and genetic studies of a patient presenting with progressive myoclonic epilepsy (121) 57

Tagaya, M., see Hata, R. (121) 79
Takino, H., see Nishiura, Y. (121) 208
Tanabe, H., see Hori, S. (121) 183
Thomas, P.K., see Patel, N.J. (121) 159
Tortosa, A., Rivera, R. and Ferrer, I.
Dose-related effects of cycloheximide on delayed neuronal death in the gerbil hippocampus after bilateral transitory forebrain ischemia (121) 10
Toyoda, K., Minematsu, K. and Yamaguchi, T.
Long-term changes in cerebral blood flow according to different types of ischemic stroke (121) 222
Tsujihata, M., see Nishiura, Y. (121) 208

Ulvestad, E., Williams, K., Vedeler, C., Antel, J., Nyland, H., Mørk, S. and Matre, R.
Reactive microglia in multiple sclerosis lesions have an increased expression of receptors for the Fc part of IgG (121) 125

Vedeler, C., see Ulvestad, E. (121) 125
Visser, J.J., see Kuiper, M.A. (121) 46
Von Giesen, H.-J., Arendt, G., Neuen-Jacob, E., Prestien, K., Jablonowski, H. and Freund, H.J.
A pathologically distinct new form of HIV associated encephalopathy (121) 215
Vonlanthen, M.G., see Dupont-Versteegden, E.E. (121) 203

Wallin, A., see Blennow, K. (121) 90
Wang, Z.-Y., see Qiao, J. (121) 190
Warren, K.G. and Catz, I.
Relative frequency of autoantibodies to myelin basic protein and proteolipid protein in optic neuritis and multiple sclerosis cerebrospinal fluid (121) 66
Weckesser, M., see Ringelstein, E.B. (121) 103
Weckesser, S., see Ringelstein, E.B. (121) 103
Weiller, C., see Ringelstein, E.B. (121) 103
Wikkelsö, C., see Blennow, K. (121) 90
Wilbourn, A.J., see Bashar Katirji, (121) 172
Williams, K., see Ulvestad, E. (121) 125
Wolters, E.C., see Kuiper, M.A. (121) 46
Wright, D.W., see Patel, N.J. (121) 159

Yamaguchi, T., see Toyoda, K. (121) 222
Yanagi, T., see Yasuda, T. (121) 97
Yanagihara, T., see Hata, R. (121) 79
Yasuda, T., Sobue, G., Doyu, M., Nakazato, M., Shiomi, K., Yanagi, T. and Mitsuma, T.
Familial amyloidotic polyneuropathy with late-onset and well-preserved autonomic function: a Japanese kindred with novel mutant transthyretin (Ala^{97} to Gly) (121) 97
Yasuda, T., see Sobue, G. (121) 167
Yoneoka, T., see Hirota, M. (121) 176
Youl, B.D., see Sweeney, M.G. (121) 57

Zimmermann, C.W., see Dux, R. (121) 74

Journal of the Neurological Sciences, 121 (1994) 236–237
Elsevier Science B.V.

Subject Index (Vol. 121)

Acetylcholine receptor, (121) 190
AIDS, (121) 215
Alzheimer's disease, (121) 46
γ-Aminobutyric acid, (121) 1
Amyotrophic lateral sclerosis, (121) 18
Androgen receptor gene, (121) 167
Antibodies, (121) 190
Anti-MBP, (121) 66
Anti-PLP, (121) 66
Atherothrombotic stroke, (121) 222
Athetosis, (121) 50
Atrophy, (121) 194
Autoimmunity, (121) 39, (121) 190
Autonomic function, (121) 97
Autopsy, (121) 132
Autoradiography, (121) 27

Becker muscular dystrophy, (121) 183
Biceps femoris, (121) 172
Biopterin, (121) 46
Blood–brain barrier (BBB), (121) 90
Brain infarction, (121) 222
β-Bungarotoxin binding protein, (121) 190

CAG repeat, (121) 167
Cerebral blood flow, (121) 222
Cerebral ischemia, (121) 27
Cerebral ischemic response, (121) 79
Cerebrospinal fluid, (121) 39, (121) 46, (121) 74
Cerebrotendinous xanthomatosis, (121) 229, (121) 231
Co-culture system, (121) 208
Collateral circulation, (121) 222
Computerized electroencephalography, (121) 1
Configuration of the circle of Willis, (121) 103
Culture, (121) 132
Cycloheximide, (121) 10
Cytochrome *P*-450db1, (121) 18
Cytokines, (121) 208

Debrisoquine, (121) 18
Delayed neuronal death, (121) 10
Dementia of the Alzheimer type, (121) 139
Diabetes, (121) 163
Diabetic neuropathy, (121) 163
Dizocilpine, (121) 110
Dorsal root ganglia, (121) 159
Double-label immunostaining, (121) 208
Down's syndrome, (121) 22
Dystrophic mouse, (121) 176
Dystrophin, (121) 183, (121) 203

EEG, (121) 110
Electromyography, (121) 172
Encephalitis, (121) 215
Epilepsy, (121) 50

Error ratio, (121) 32
Event-related potentials, (121) 22; (121) 139
Excitatory amino acids, (121) 110
Experimental autoimmune myasthenia gravis, (121) 190

Familial amyloidotic polyneuropathy (FAP), (121) 97
Fc receptors, (121) 125
Fiber size, (121) 194
Fiber type, (121) 194
Flow cytometry, (121) 74
Focal cerebral ischemia, (121) 110
Follicle-stimulating hormone (FSH), (121) 167
Foot drop, (121) 172

Gel electrophoresis, two-dimensional, (121) 183
Gerbil, (121) 10, (121) 79
Glucose, (121) 159
Glutamate, (121) 1
Granulocyte-macrophage colony stimulating factor, (121) 208

Hearing deficit, (121) 50
Heat shock protein, (121) 10
Hindbrain ischemia, (121) 79
Hippocampus, (121) 10
Histochemistry, (121) 194
Histology, (121) 110
HIV, (121) 215
Hodgkin's disease, (121) 155
Human glioma cell, (121) 208
Human T-lymphotropic virus type I, (121) 208
Huntington's disease, (121) 147
Hydrocephalus, (121) 32
Hypertonia, (121) 147
Hypertrophy, (121) 194

ICA occlusion, (121) 103
Immunoglobulin G (IgG), (121) 90
Immunohistochemistry, (121) 79, (121) 125
Infantile onset cerebellar ataxia, (121) 50
Inflammatory demyelinating neuropathy, (121) 155
Insulin, (121) 159, (121) 163
Intrathecal IgG production, (121) 90
Ischemia, (121) 10

Kaolin, (121) 32

Late onset, (121) 97
LDL-apheresis, (121) 229, (121) 231
Leigh's syndrome, (121) 57
Leucine, (121) 159
Leukoencephalopathy, (121) 215
Luteinizing hormone (LH), (121) 167

Malignant cells, (121) 74
Markers, (121) 132

mdx, (121) 176
mdx mouse, (121) 203
MERRF, (121) 57
Metabolic rate, (121) 203
Mickey Mouse, (121) 22
Microglia, (121) 125
Microtubule-associated protein 2, (121) 79
Mitochondrial DNA, (121) 57
MK-801, (121) 110
Mongolian gerbil, (121) 18
Monoclonal antibodies, (121) 74
MPTP, (121) 18
MRI, (121) 215
Multiple sclerosis, (121) 66, (121) 125
Multiple system atrophy, (121) 46
Muscarinic acetylcholine, (121) 27
Muscle, (121) 203
Muscle tone, (121) 147
Muscular dystrophy, (121) 203
Mutant transthyretin (Ala^{97} to Gly), (121) 97

Nerve growth factor, (121) 163, (121) 176
Neurodegeneration, (121) 46
Neurofilaments, (121) 132
Neuron, (121) 132
Neuropathology, (121) 125, (121) 215
Neurotoxin, (121) 18
Nitrate, (121) 46
Nitric oxide, (121) 46
Nitrite, (121) 46
Novel stimuli, (121) 22

Operant task, (121) 32
Ophthalmoplegia, (121) 50
Optic atrophy, (121) 50
Optic neuritis, (121) 66
Oxygen consumption, (121) 203

P300, (121) 139
Paraneoplastic syndrome, (121) 155
Parkinson's disease, (121) 18, (121) 39, (121) 46, (121) 139
Pattern of brain infarction, (121) 103
Pentylene tetrazole, (121) 1
Peripheral neuropathy, (121) 155
Peroneal nerve, (121) 172
Picrotoxin, (121) 1
Postischemic neuronal damage, (121) 27
Pyridoxine-deficiency, (121) 1

Reaction time, (121) 32
Rigidity, (121) 147

Sciatic nerve, (121) 172
Seizures, (121) 1
Sensory neuropathy, (121) 50
Skeletal muscle, (121) 194
Somatosensory, (121) 139
Submaxillary gland, (121) 176

$\gamma\delta^+$ T cell, (121) 39
Testosterone, (121) 167, (121) 176
Thyroxine, (121) 176
TIQ, (121) 18
Tonic stretch reflex, (121) 147

Uptake, (121) 159

Vascular dementia, (121) 139
Vasomotor reactivity, (121) 103
Visual stimulation, (121) 22

Xenon-133 inhalation method, (121) 222
X-linked recessive bulbospinal neuronopathy, (121) 167